Yulia M. Mikhailova
Yulia M. Mikhailova has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Olga E. Ivanova
Federal State Autonomous Scientific Institution “Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences” (Institute of Poliomyelitis) (FSASI “Chumakov FSC R&D IBP RAS”), 108819 Moscow, Russia
5 shared publications - Liubov I. Kozlovskaya
Federal State Autonomous Scientific Institution “Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences” (Institute of Poliomyelitis) (FSASI “Chumakov FSC R&D IBP RAS”), 108819 Moscow, Russia
4 shared publications - Alina V. Chirova
Federal Budgetary Health Institution “Federal Center of Hygiene and Epidemiology” of the Federal Office for Inspectorate in the Field of Customers and Human Well-Being Protection, 117105 Moscow, Russia
2 shared publications - Alina V. Chirova
Federal Center of Hygiene and Epidemiology
2 shared publications - Armen K. Shakaryan
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
2 shared publications - Elizaveta V. Yakovchuk
Federal State Autonomous Scientific Institution “Chumakov Federal Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences” (Institute of Poliomyelitis) (FSASI “Chumakov FSC R&D IBP RAS”), 108819 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (3) , 297-310
Epidemiological surveillance for poliomyelitis and acute flaccid paralysis in the Russian Federation in 2013–2024
Introduction. The goal of the WHO Global Polio Eradication Initiative has not yet been solved, and the surveillance of diseases with acute flaccid paralysis (AFP) remains its key element. It is still relevant for ensuring the sanitary and epidemiological well-being of Russia. Aim: analysis of indicators and results of polio/AFP surveillance in 2013-2024 for purposes of surveillance quality assessment and improvement. Materials and methods. Information on surveillance indicators and results of virological investigation was obtained in national reporting documents. Results. Over 12 years, 5,016 cases of AFP have been registered. Surveillance quality indicators were generally in line with WHO recommendations, but the COVID-19 pandemic had a negative impact on the detection of AFP cases at the clinical level. The majority of patients were children under 5 years of age (50.54%), boys (58.8%), the majority (82.46%) were vaccinated against polio. Polioviruses (PV) were isolated from 1.85% of cases, PV3 (48.4%) prevailed, non-polio enteroviruses — from 1.46% cases, CVB1–6 (34.9%) and EV-A71 (17.5%) were predominant. The majority of AFP cases (30.78%) were polyradiculoneuropathies, 34 cases (0.68%) were poliomyelitis. The occurrence of 30 cases of vaccine-associated paralytic poliomyelitis was associated with violations of sanitary and epidemiological requirements for its prevention. Four cases were associated with PV of vaccine origin (VDPV) types 1 and 3. The "age" of VDPVs corresponded to 1-2 years of circulation, there was no genetic evidence of human-to-human transmission. Conclusion. High level of polio/AFP surveillance in Russia allowed to identify epidemiologically significant PVs and timely carry out anti-epidemic measures. The continuing threat of the international spread of poliomyelitis is the basis for future improving surveillance. The surveillance platform provides information about other (non-polio) pathogens that cause diseases with AFP syndrome.
- 30 June 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (3) , 297-310
Open AccessEpidemiological surveillance for poliomyelitis and acute flaccid paralysis in the Russian Federation in 2013–2024
Introduction. The goal of the WHO Global Polio Eradication Initiative has not yet been solved, and the surveillance of diseases with acute flaccid paralysis (AFP) remains its key element. It is still relevant for ensuring the sanitary and epidemiological well-being of Russia. Aim: analysis of indicators and results of polio/AFP surveillance in 2013-2024 for purposes of surveillance quality assessment and improvement. Materials and methods. Information on surveillance indicators and results of virological investigation was obtained in national reporting documents. Results. Over 12 years, 5,016 cases of AFP have been registered. Surveillance quality indicators were generally in line with WHO recommendations, but the COVID-19 pandemic had a negative impact on the detection of AFP cases at the clinical level. The majority of patients were children under 5 years of age (50.54%), boys (58.8%), the majority (82.46%) were vaccinated against polio. Polioviruses (PV) were isolated from 1.85% of cases, PV3 (48.4%) prevailed, non-polio enteroviruses — from 1.46% cases, CVB1–6 (34.9%) and EV-A71 (17.5%) were predominant. The majority of AFP cases (30.78%) were polyradiculoneuropathies, 34 cases (0.68%) were poliomyelitis. The occurrence of 30 cases of vaccine-associated paralytic poliomyelitis was associated with violations of sanitary and epidemiological requirements for its prevention. Four cases were associated with PV of vaccine origin (VDPV) types 1 and 3. The "age" of VDPVs corresponded to 1-2 years of circulation, there was no genetic evidence of human-to-human transmission. Conclusion. High level of polio/AFP surveillance in Russia allowed to identify epidemiologically significant PVs and timely carry out anti-epidemic measures. The continuing threat of the international spread of poliomyelitis is the basis for future improving surveillance. The surveillance platform provides information about other (non-polio) pathogens that cause diseases with AFP syndrome.
- 25 November 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70704
Acute Flaccid Paralysis in a Vaccinated Child With Primary Immunodeficiency: Difficulties With Diagnostics of Vaccine‐Associated Paralytic Poliomyelitis
Oral polio vaccine (OPV) from attenuated Sabin strains widely used for poliomyelitis prevention and eradication along with undeniable advantages has significant disadvantages, one of which is the ability to cause cases of vaccine‐associated paralytic poliomyelitis (VAPP). Inactivated poliovirus vaccine (IPV) introduction into the national immunization schedules of countries that continue to use OPV allows effective prevention of VAPP cases and simultaneously forms immunity to PV type 2. The present study presents an example of VAPP development in a child with Bruton's disease, born by in vitro fertilization, vaccinated with four IPV doses followed by one bOPV dose, and paralysis onset 52 days bOPV vaccination. Despite objective clinical, laboratory and instrumental signs of anterior corneal myelitis, the isolation of Sabin‐like poliovirus, and contradictory results of serological investigation, diagnostics caused significant difficulties for the treating physicians. The case was associated with a recombinant poliovirus of vaccine Sabin strains types 3 and 1 with a recombination point in 2C‐encoding genome region, containing known neurovirulence reverse mutations and some unique ones. The introduction of IPV doses for primary immunization increases the safety of immunization against polio; however, while OPV is in use there is still a VAPP threat for immunocompromised children and unvaccinated contacts.
- 25 November 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70704
Acute Flaccid Paralysis in a Vaccinated Child With Primary Immunodeficiency: Difficulties With Diagnostics of Vaccine‐Associated Paralytic Poliomyelitis
Oral polio vaccine (OPV) from attenuated Sabin strains widely used for poliomyelitis prevention and eradication along with undeniable advantages has significant disadvantages, one of which is the ability to cause cases of vaccine‐associated paralytic poliomyelitis (VAPP). Inactivated poliovirus vaccine (IPV) introduction into the national immunization schedules of countries that continue to use OPV allows effective prevention of VAPP cases and simultaneously forms immunity to PV type 2. The present study presents an example of VAPP development in a child with Bruton's disease, born by in vitro fertilization, vaccinated with four IPV doses followed by one bOPV dose, and paralysis onset 52 days bOPV vaccination. Despite objective clinical, laboratory and instrumental signs of anterior corneal myelitis, the isolation of Sabin‐like poliovirus, and contradictory results of serological investigation, diagnostics caused significant difficulties for the treating physicians. The case was associated with a recombinant poliovirus of vaccine Sabin strains types 3 and 1 with a recombination point in 2C‐encoding genome region, containing known neurovirulence reverse mutations and some unique ones. The introduction of IPV doses for primary immunization increases the safety of immunization against polio; however, while OPV is in use there is still a VAPP threat for immunocompromised children and unvaccinated contacts.
- Open Access
Supplementary Surveillance of Poliovirus Circulation in the Russian Federation: Results of a Study on Migrant Children of “Risk Group”
The detection of “silent” poliovirus (PV) circulation among clinically healthy populations is an important component of supplementary surveillance for poliomyelitis. Migrants from countries or regions where polio is endemic, affected by outbreaks, or at risk may contribute to the introduction of PVs of epidemic significance: wild poliovirus type 1, vaccine-derived polioviruses (VDPVs), or poliovirus type 2 into polio-free countries. Migrant children, refugees under 5 years of age, are considered a “risk group” in Russia and are subject to testing for PVs. During 2014–2023, guided by the algorithm of virological and molecular investigation of acute flaccid paralysis cases recommended by the WHO, 51,548 migrant children, arriving from 40 countries, were examined. Among 4% of children excreting various cytopathogenic viruses, polio excretors accounted for 20.8%. Among the PVs, PV3 was predominant (41.7%), and PV types 2, 1, and a mixture of PVs accounted for, respectively, 28.2%, 18.8%, and 11.3%. All isolates of PVs 1 and 3 were identified as Sabin-like. The detection of five children excreting epidemically significant PV2 (four VDPV2 and one Sabin-like) required an assessment of the risk of dissemination and additional immunization activities. Among 580 identified isolates of NPEV, the most abundant was the E. betacoxsakie species at 73.8% (CVB1–6, E11, E6, E13, E7). Information on NPEVs expands our knowledge of the spectrum of NPEVs circulating among healthy children worldwide, but its prognostic significance is still unclear. The detection of PVs in children from the “risk group” allows targeted anti-epidemic measures and is a significant advantage of this type of supplementary surveillance for polio.
Open AccessSupplementary Surveillance of Poliovirus Circulation in the Russian Federation: Results of a Study on Migrant Children of “Risk Group”
The detection of “silent” poliovirus (PV) circulation among clinically healthy populations is an important component of supplementary surveillance for poliomyelitis. Migrants from countries or regions where polio is endemic, affected by outbreaks, or at risk may contribute to the introduction of PVs of epidemic significance: wild poliovirus type 1, vaccine-derived polioviruses (VDPVs), or poliovirus type 2 into polio-free countries. Migrant children, refugees under 5 years of age, are considered a “risk group” in Russia and are subject to testing for PVs. During 2014–2023, guided by the algorithm of virological and molecular investigation of acute flaccid paralysis cases recommended by the WHO, 51,548 migrant children, arriving from 40 countries, were examined. Among 4% of children excreting various cytopathogenic viruses, polio excretors accounted for 20.8%. Among the PVs, PV3 was predominant (41.7%), and PV types 2, 1, and a mixture of PVs accounted for, respectively, 28.2%, 18.8%, and 11.3%. All isolates of PVs 1 and 3 were identified as Sabin-like. The detection of five children excreting epidemically significant PV2 (four VDPV2 and one Sabin-like) required an assessment of the risk of dissemination and additional immunization activities. Among 580 identified isolates of NPEV, the most abundant was the E. betacoxsakie species at 73.8% (CVB1–6, E11, E6, E13, E7). Information on NPEVs expands our knowledge of the spectrum of NPEVs circulating among healthy children worldwide, but its prognostic significance is still unclear. The detection of PVs in children from the “risk group” allows targeted anti-epidemic measures and is a significant advantage of this type of supplementary surveillance for polio.
- Open Access
- 16 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (11) , 1104-1109
Problems of poliomyelitis eradication
The article is devoted to the problems of implementation of the WHO Global Polio Eradication Initiative. The influence of the features of poliovirus infection and poliovirus vaccines on the course of the program, its successes and difficulties is considered, the issue of possibility of eradication this infection is discussed.
- 16 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (11) , 1104-1109
Open AccessProblems of poliomyelitis eradication
The article is devoted to the problems of implementation of the WHO Global Polio Eradication Initiative. The influence of the features of poliovirus infection and poliovirus vaccines on the course of the program, its successes and difficulties is considered, the issue of possibility of eradication this infection is discussed.
- Open Access
Detection of Polioviruses Type 2 among Migrant Children Arriving to the Russian Federation from a Country with a Registered Poliomyelitis Outbreak
The widespread use of the oral poliovaccine from Sabin strains (tOPV) radically reduced poliomyelitis incidence worldwide. However, OPV became a source of neurovirulent vaccine-derived polioviruses (VDPVs). Currently, circulating type 2 VDPVs (cVDPV2) are the leading cause of poliomyelitis. The novel OPV type 2 vaccine (nOPV2), based on genetically modified Sabin strain with increased genetic stability and reduced risk of cVDPV formation, has been used to combat cVDPV2 outbreaks, including one in Tajikistan in 2021. In order to identify the importation of cVDPV2 and nOPV2-derivates, stool samples from 12,127 healthy migrant children under 5 years of age arriving from Tajikistan were examined in Russia (March 2021–April 2022). Viruses were isolated in cell culture and identified via intratype differentiation RT-PCR, VP1 and whole-genome sequencing. cVDPV2 isolates closely related with the Tajikistan one were isolated from two children, and nOPV2-derived viruses were detected in specimens from 106 children from 37 regions of Russia. The duration of nOPV2 excretion ranged from 24 to 124 days post-vaccination. nOPV2 isolates contained 27 mutations per genome (0.36%) on average, with no critical genetic changes, which confirms the genetic stability of nOPV2 during field use. The possibility of epidemiologically significant poliovirus introduction into polio-free countries has been confirmed. The screening of special populations, including migrants, is required to maintain epidemiological well-being.
Open AccessDetection of Polioviruses Type 2 among Migrant Children Arriving to the Russian Federation from a Country with a Registered Poliomyelitis Outbreak
The widespread use of the oral poliovaccine from Sabin strains (tOPV) radically reduced poliomyelitis incidence worldwide. However, OPV became a source of neurovirulent vaccine-derived polioviruses (VDPVs). Currently, circulating type 2 VDPVs (cVDPV2) are the leading cause of poliomyelitis. The novel OPV type 2 vaccine (nOPV2), based on genetically modified Sabin strain with increased genetic stability and reduced risk of cVDPV formation, has been used to combat cVDPV2 outbreaks, including one in Tajikistan in 2021. In order to identify the importation of cVDPV2 and nOPV2-derivates, stool samples from 12,127 healthy migrant children under 5 years of age arriving from Tajikistan were examined in Russia (March 2021–April 2022). Viruses were isolated in cell culture and identified via intratype differentiation RT-PCR, VP1 and whole-genome sequencing. cVDPV2 isolates closely related with the Tajikistan one were isolated from two children, and nOPV2-derived viruses were detected in specimens from 106 children from 37 regions of Russia. The duration of nOPV2 excretion ranged from 24 to 124 days post-vaccination. nOPV2 isolates contained 27 mutations per genome (0.36%) on average, with no critical genetic changes, which confirms the genetic stability of nOPV2 during field use. The possibility of epidemiologically significant poliovirus introduction into polio-free countries has been confirmed. The screening of special populations, including migrants, is required to maintain epidemiological well-being.